These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 25099154)

  • 1. Biologic therapy improves psoriasis by decreasing the activity of monocytes and neutrophils.
    Yamanaka K; Umezawa Y; Yamagiwa A; Saeki H; Kondo M; Gabazza EC; Nakagawa H; Mizutani H
    J Dermatol; 2014 Aug; 41(8):679-85. PubMed ID: 25099154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
    Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
    Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a.
    Leonardi CL
    Semin Cutan Med Surg; 2016 Jun; 35(4 Suppl 4):S74-7. PubMed ID: 27551698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adhesion of peripheral blood mononuclear cells and CD4+ T cells from patients with psoriasis to cultured endothelial cells via the interaction between lymphocyte function-associated antigen type 1 and intercellular adhesion molecule 1.
    Watabe D; Kanno H; Yoshida A; Kurose A; Akasaka T; Sawai T
    Br J Dermatol; 2007 Aug; 157(2):259-65. PubMed ID: 17596165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Ustekinumab in a patient with Crohn's disease and anti-TNF-α-induced psoriasis].
    Sansó Sureda A; Rocamora Durán V; Sapiña Camaró A; Royo Escosa V; Bosque López MJ
    Gastroenterol Hepatol; 2011 Oct; 34(8):546-50. PubMed ID: 21665330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depressed interleukin-12-producing activity by monocytes correlates with adverse clinical course and a shift toward Th2-type lymphocyte pattern in severely injured male trauma patients.
    Spolarics Z; Siddiqi M; Siegel JH; Garcia ZC; Stein DS; Denny T; Deitch EA
    Crit Care Med; 2003 Jun; 31(6):1722-9. PubMed ID: 12794411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
    Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
    Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues.
    Bosè F; Raeli L; Garutti C; Frigerio E; Cozzi A; Crimi M; Caprioli F; Scavelli R; Altomare G; Geginat J; Abrignani S; Reali E
    Clin Immunol; 2011 May; 139(2):164-76. PubMed ID: 21334981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ustekinumab improves psoriasis without altering T cell cytokine production, differentiation, and T cell receptor repertoire diversity.
    Tsuda K; Yamanaka K; Kondo M; Matsubara K; Sasaki R; Tomimoto H; Gabazza EC; Mizutani H
    PLoS One; 2012; 7(12):e51819. PubMed ID: 23251632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
    Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
    Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab induces downregulation of the IL-12/IL-23 axis in 6-sulfo-LacNac (slan)+ dendritic cells and macrophages.
    Brunner PM; Koszik F; Reininger B; Kalb ML; Bauer W; Stingl G
    J Allergy Clin Immunol; 2013 Nov; 132(5):1184-1193.e8. PubMed ID: 23890755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha?
    Cuchacovich R; Espinoza CG; Virk Z; Espinoza LR
    J Clin Rheumatol; 2008 Dec; 14(6):353-6. PubMed ID: 19033869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adsorptive depletion of CD14⁺CD16⁺ proinflammatory monocyte phenotype in patients with generalized pustular psoriasis: clinical efficacy and effects on cytokines.
    Fujisawa T; Murase K; Kanoh H; Takemura M; Ohnishi H; Seishima M
    Ther Apher Dial; 2012 Oct; 16(5):436-44. PubMed ID: 23046368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal gammopathy of undetermined significance in patients with psoriasis: is it really a side effect of biological therapy?
    Conti A; Esposito I; Lasagni C; Miglietta R; Padalino C; Fabiano A; Pellacani G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S35-7. PubMed ID: 25381972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte colony-stimulating-factor-induced psoriasiform dermatitis resembles psoriasis with regard to abnormal cytokine expression and epidermal activation.
    Mössner R; Beckmann I; Hallermann C; Neumann C; Reich K
    Exp Dermatol; 2004 Jun; 13(6):340-6. PubMed ID: 15186319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
    Leman J; Burden AD
    Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of patients with psoriasis treated with biological drugs needing a surgical treatment.
    Fabiano A; De Simone C; Gisondi P; Piaserico S; Lasagni C; Pellacani G; Conti A
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S24-6. PubMed ID: 25381969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic fatigue in psoriasis.
    Levin EC; Gupta R; Brown G; Malakouti M; Koo J
    J Dermatolog Treat; 2014 Feb; 25(1):78-82. PubMed ID: 23875537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
    Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
    J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.